MedTrace Logo

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

NCT00634959 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2010-11-10

No results posted yet for this study

Summary

To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)

Conditions

Interventions

DRUG

Maraviroc (UK-427,857)

150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)

DRUG

Maraviroc (UK-427,857)

100 mg oral tablet once daily while fasted on Days 1-10

DRUG

Maraviroc (UK-427,857)

300 mg oral tablet once daily while fasted on Days 1-10

DRUG

Maraviroc (UK-427,857)

150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)

OTHER

Placebo

Matching placebo oral tablet on Days 1-10 (fed and fasted)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Completion
2003-12-31

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00634959 on ClinicalTrials.gov